Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ (2013). Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension. Vasc. Health Risk Manag. 9:763-768.
crossref

Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ (2010). Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 56(6):967-76.
crossref

Andrew JK, Clifford JB (1994). Type 2 diabetes. London: Royal Society of Medicine Press. p. 107

Bakogianni MC, Kalofoutis CA, Skenderi KI, Kalofoutis AT (2001). Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin dependent diabetics with coronary disease. J. Diabetes Complications 15(5):265-269.
crossref

Cai L, Zhang L, Liu A, Li S, Wang P (2012). Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China. J. Atheroscler. Thromb. 19:159-168.
crossref

Dobiasova M, Stribrna J, Pritchard P, Frohlich J (1992). Cholesterol esterification rate in plasma depleted of very low and low density lipoprotein is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle aged and septuagenarian men. J. Lipid Res. 33:1411-1418.

DurakoÄŸlugil ME, Ayaz T, Kocaman SA, KırbaÅŸ A, DurakoÄŸlugil T, ErdoÄŸan T, Çetin M, Åžahin OZ, Çiçek Y (2014).The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anadolu Kardiyol Derg. 2014 Jul 17.
crossref

Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, et al (2004). Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 50:1189-1200.
crossref

Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y (2008). A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J. Lipid Res. 49(5):1130-1136.
crossref

Iaccarino G, Trimarco V, Lanni F, Cipolletta E, Izzo R, Arcucci O, De Luca N and Di Renzo G (2005). β-Blockade and increased dyslipidemia in patients bearing Glu27 variant of β2 adrenergic receptor gene. Pharmacogenomics J. 5:292-297
crossref

Joy T and Hegele RA (2008). Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7:143-155.
crossref

Kanaya AM, Vittinghoff E, Shlipak MG, Resnick HE, Visser M, Grady D, Barrett-Connor E (2003). Association of total and central obesity with mortality in postmenopausal women with coronary heart disease. Am. J. Epidemiol.158:1161-1170.
crossref

Maeda S, Nakanishi S, Yoneda M, Awaya T, Yamane K, Hirano T, Kohno N (2012). Associations between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. J. Atheroscler. Thromb. 19(5):444-52
crossref

McPherson R, Frohlich J, Fodor G, Genest J (2006). Canadian Cardiovascular Society position statement ‐ Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22:913‐27.
crossref

Moriyama K, Negami M, Takahashi E (2014). HDL2-cholesterol/HDL3-cholesterol ratio was associated with insulin resistance, high-molecular-weight adiponectin and components for metabolic syndrome in Japanese Diabetes. Res. Clin. Pract. 106(2):360-365.
crossref

Okeahialam BN, Osunkwo A, Isichei CO (2008). Artherogenic burden of hypertensive, diabetic and hypertensive – diabetic patients seen in Jos. J. Med. Trop. 5:50-55.

Saidu H, Karaye KM, Okeahialam BN (2014). Plasma lipid profile in Nigerians with high--normal blood pressure. BMC Res. Notes 7:930.

Shuhei N, Söderlund S, Jauhiainen M, Taskinen MR (2010). Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis. 9(1):104-114.
crossref

Skoczyńska A, Wojakowska A, Turczyn B, Zatońska K, Wołyniec M, Regulska-Ilow B, Ilow R, Szuba A, Zatoński W (2013). Lipid pattern in middle-aged inhabitants of the Lower Silesian region of Poland. The PURE Poland sub-study. Ann. Agric. Environ. Med. 20(2):317-24

Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll MH (2011). Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am. J. Clin. Pathol. 136(1):20-9.
crossref

Stone NJ, Bilek S, Rosenbaum S.Strona NCEPT ATP III (2005). Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am. J. Cardiol. 96(4A): 53E-59E.
crossref

Sun GZ, Li Z, Guo L, Zhou Y, Yang HM, Sun YX (2014). High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis.13(1):189.
crossref

Superko HR (2009). Advanced Lipoprotein Testing and Subfractionation are Clinically Useful. Circulation 119:2383-2395.
crossref

Szollár LG, Mészáros I, Tornóci L, Rischák K, Molnár M, Mányai S (1990). Effect of metoprolol and pindolol monotherapy on plasma lipid and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females. J. Cardiovasc. Pharmacol. 15(6):911-917.
crossref

Thalameh Y, Wei R, Naito H (1986). Measurement of HDL HDL2, and HDL3 by HDL3 by dextran sulfate –MgCl2 precipitation technique in human serum. Clin. Chim. Acta 158:33-41.
crossref

Van Linthout S, Spillmann F, Schultheiss HP; Tschope, C (2010). High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr. Pharm. Des. 16(13):1504-1516.
crossref

Vassault A, Grafmeyer D, de Graeve J, Cohen R, Beaudonnet A, Bienvenu J (1999). Analyse de biologie médicale : spécification et normes d'acceptabilité à l'usage de la validation de techniques. Ann. Biol. Clin.57: 685-95.

Wang B, Wei D, Wang C, Zhang J, Pan L, Ma M, Xue F, Wu Z, Shan G (2012). Prevalence of dyslipidemia and associated factors in the Yi farmers and migrants of Southwestern China. Atherosclerosis 223:512-518.
crossref